Segment Information (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The following table summarizes our segment revenue, significant segment expenses, and segment profit:

	2024		2023		2022
Revenue	$	45,042.7	$	34,124.1	$	28,541.4
Less:
Cost of sales	8,418.3		7,082.2		6,629.8
Early-stage research and development(1)	3,916.9		3,092.5		2,406.6
Late-stage research and development(1)	7,073.7		6,220.9		4,784.2
Marketing, selling, and administrative	8,593.8		7,403.1		6,440.4
Acquired in-process research and development	3,280.4		3,799.8		908.5
Other segment items(2)	3,169.6		1,285.2		1,127.1
Net income	$	10,590.0	$	5,240.4	$	6,244.8

(1) Early-stage research and development primarily includes costs incurred from discovery through Phase 2 clinical trials. Late-stage research and development primarily includes costs incurred from Phase 3 clinical trials.

(2) Other segment items primarily include income taxes and asset impairment, restructuring, and other special charges.

The following tables summarize additional segment information:

	2024		2023		2022
Interest income	$	175.2	$	173.6	$	62.8
Interest expense	780.6		485.9		331.6
Depreciation and amortization	1,766.6		1,527.3		1,522.5
Asset impairment, restructuring, and other special charges	860.6		67.7		244.6
Earnings (loss) in equity method investments	89.8		(10.1)		(138.0)
Income taxes	2,090.4		1,314.2		561.6
Expenditures for long-lived assets(1)	5,560.8		3,830.2		2,289.2

(1) Includes expenditures for property and equipment and computer software costs.

	2024		2023
Total assets	$	78,714.9	$	64,006.3
Equity method investments	1,142.7		962.3